title: Rituximab in bronchiolitis obliterans after haematopoietic stem cell transplantation.
authors.forename: G
authors.initials: G
authors.lastname: Lorillon
authors.forename: M
authors.initials: M
authors.lastname: Robin
authors.forename: V
authors.initials: V
authors.lastname: Meignin
authors.forename: P
authors.initials: P
authors.lastname: Ribaud
authors.forename: B
authors.initials: B
authors.lastname: Lescoeur
authors.forename: D
authors.initials: D
authors.lastname: Gossot
authors.forename: G
authors.initials: G
authors.lastname: Socié
authors.forename: A
authors.initials: A
authors.lastname: Tazi
authors.forename: A
authors.initials: A
authors.lastname: Bergeron
mesh_terms: D000293:Adolescent; D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D001989:Bronchiolitis Obliterans / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D001993:Bronchodilator Agents / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000188:drug therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents; D018942:Macrolides / Q000627:therapeutic use; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D016559:Tacrolimus / Q000627:therapeutic use; D019172:Transplantation Conditioning; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001993:Bronchodilator Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D018942:Macrolides; D000069283:Rituximab; D009173:Mycophenolic Acid; D011241:Prednisone; D016559:Tacrolimus